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Transforming growth factor beta increases the expression of HIV-1
gene in transfected human mesangial cells. Human immunodeficiency
virus type 1 (HIV) infection is often complicated by focal glomerulo-
sclerosis (FGS) and other renal lesions collectively termed HIV asso-
ciated nephropathy (HIVAN). FGS is characterized by glomerular
mesangial expansion and increased synthesis of matrix components.
The molecular pathogenic mechanisms associated with the develop-
ment of HIV associated nephropathy are unknown. Experimental
animal models suggest a role for cytokines and growth factors, partic-
ularly transforming growth factor /3 (TGF-13), in the pathogenesis of
glomeruloscierosis. Patients with AIDS have elevated plasma and
tissue levels of TGF-/3. We carried out experiments to determine
whether primary human mesangial cells (HMC) in culture can be
transfected with HIV-l genes. HMC were transfected with a chloram-
phenicol acetyl transferase (CAT) reporter construct containing HIV-l
LTR sequences. Our results show successful transfection of HMC with
HIV-1 LTR gene. HMC transfected with LTR gene are responsive to
the HIV-1 regulatory gene product Tat. To study whether TGF-13 can
modulate the expression of HIV-l LTR gene in HMC, HMC transfected
with an HIV-1 LTR CAT plasmid were treated with TGF-13 and other
growth factors two hours before harvest. TGF-/3 specifically increased
the expression of the HIV-1 gene in HMC in a dose dependent manner.
We further studied whether up-regulation of HIV-l LTR expression in
HMC was mediated by the effect of TGF-/3 on the interaction of
transcription factors to their binding sites. Our results suggest that
TOF-/3 treatment of HMC does not effect the binding of NF-KB, NF-1,
or US-F transcription factors to their respective binding sites. Since
patients with AIDS have elevated plasma and tissue levels of TGF-/3,
our results may indicate that HIV-l gene expression in renal tissue, in
the presence of increased levels of TGF-/3, may contribute to the
pathogenesis of HIV associated nephropathy. The mechanisms under-
lying the effect of TGF-/3 on HIV-l gene expression in HMC and their
relationship to the pathogenesis of renal disease are currently unknown
and require further study.
HIV infection may be complicated by FHV-associated ne-
phropathy (HIVAN), which may be present in up to 40% of
patients if proteinuria is taken as the index of disease [1]. Renal
complications seem to affect specific subsets of patients [1, 2]
suggesting a host response or genetic component associated
with the incidence of the disease. The pathogenesis of HIV-
associated focal glomeruloscierosis (FGS), glomerulonephritis
and other renal syndromes encountered in HIV infected pa-
tients, and the mechanisms involved in the rapid progression of
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renal disease, are largely unknown. Recent evidence suggests
that HIV genetic material may be demonstrated in renal tissue
of patients with HIV infection and renal disease [3—6] and that
mesangial cells can be infected with HIV [7, 8]. Studies from
our laboratories have suggested that portions of the HIV
genome can be demonstrated in renal tissue from most HIV
infected patients with renal disease [5. Therefore, understand-
ing the pathogenesis of such renal disease might lead to preven-
tive or ameliorative strategies.
Cytokines and growth factors are strongly mitogenic to
mesangial cells [9]. The role of one such peptide, transforming
growth factor-/3 (TGF-/3), has been shown in the pathogenesis
of experimental glomeruloscierosis [10—12]. TGF-13 increases
the expression of mesangial matrix components such as lami-
nm, fibronectin and collagen type IV in experimental glomeru-
lonephntis [10—12] resulting in expansion of the mesangium.
TGF-f3 is a bifunctional regulator of cell proliferation in HMC
and other cell types [12, 13]. HMC can synthesize TGF-/3, but
may also be exposed to TGF-/3 produced in other cells [12, 13].
Treatment with anti-TGF-/3 antibodies has been shown to
abrogate disease in an animal model of glomerulonephritis [14].
Elevated TGF-p levels in plasma as well as in tissues have
been reported in patients with AIDS [15, 16]. A cell specific
effect of TGF-/3 on HIV- 1 replication has been reported in in
vitro conditions [17, 18]. Mitogenic stimulation of T cells and
monocytes harboring HIV-1 by cytokines and growth factors
plays a critical role in the activation of latent HIV-1 virus [19].
Additionally, certain cytokines and growth factors trans-acti-
vate the long terminal repeat segment (LTR) of HIV-1 [19, 20].
In order to determine whether infection of renal cells with
HIV alters cell responses, we transfected HMC with an HIV-1
LTR gene containing a chioramphenicol acetyl transferase
(CAT) reporter construct. Cotransfection of HMC with the
HIV- 1 regulatory gene tat resulted in an increase in the expres-
sion of the HIV-1 LTR CAT reporter, showing that the trans-
fected HIV-1 gene was functional. TGF-f3 increased the expres-
sion of HIV- 1 LTR in HMC in cell culture in a dose dependent
fashion, while in contrast, there was no effect of the other
growth factors tested.
Methods
Maintenance of human mesangial cells in tissue culture
Primary human mesangial cells (HMC) at passage 4-6 were
obtained from the laboratory of Dr. H. Abboud. HMC were
grown and maintained in Waymouth's 751 culture medium
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supplemented with 20% fetal calf serum, 0.6 U/mI insulin, 2 ms'i
glutamine, 1 mri sodium pyruvate, 0.1 m nonessential amino
acids and antibiotic-antifungal solution. Experiments were per-
formed on cells in passage 6-10 [21].
Transfection of HMC with HIV-I LTR CAT plasmid
To investigate whether primary cell cultures of HMC can be
infected and express HIV-l genes, we transfected HMC in cell
culture with a chloramphenicol acetyl transferase (CAT) re-
porter plasmid containing the 5'-LTR segment of the HIV-l
genome. We monitored HIV-1 gene expression by the CAT
enzyme assay. CAT is a bacterial enzyme which catalyzes the
acetylation of chloramphenicol. Since mammalian cells do not
synthesize CAT, the presence of this enzyme activity in trans-
fected cells serves as an index of the expression of the trans-
fected gene.
Cells grown to 90% confluence were harvested with trypsin
EDTA solution. 0.5 x 106 cells were seeded in 60 mm tissue
culture plates containing 5 ml of supplemented culture medium.
When the cells were 60 to 70% confluent, they were transfected
with the HIV-1 LTR CAT reporter plasmid by a calcium
phosphate precipitation method [22]. The plasmid, termed pBen
CAT, was constructed by first cloning a segment of the HIV- 1
genome, containing the 5' LTR sequences and + 1 to +80
nucleotides, in a pBR322 vector, followed by the cloning of the
CAT reporter gene downstream of HIV-1 sequences [23]. In
brief, 17 jsg DNA (3 to 6 jsg plasmid DNA plus 11 to 14 jsg
herring sperm DNA as carrier/plate) (Sigma Chemical Co., St.
Louis, Missouri, USA) were added to 2 m buffered calcium
phosphate solution and incubated for 10 to 15 minutes until a
fine precipitate was visible. The DNA-calcium phosphate sus-
pension was gently layered over the cells, which were incu-
bated overnight at 35°C and 3.5% CO2. After 24 hours the
culture medium was removed; cells were rinsed and supple-
mented with fresh medium and incubated at 37°C and 5% CO2
concentration. Cells were rinsed with phosphate buffered sa-
line, harvested, and cytoplasmic lysates were prepared by
freezing and thawing the cells in Tris buffer. CAT enzyme
activity was assayed in the cytoplasmic lysates [22]. The
enzyme assay system contained C14 chloramphenicol and
acetyl CoA. The reaction products were separated by thin layer
chromatography (TLC). TLC plates were exposed to X-ray
film. Radioactive spots scraped from the plates were counted in
a scintillation counter for determination of radioactivity.
All the transfections were carried out in triplicate. HeLa cells
were used as controls to monitor the efficiency of transfection in
the initial experiments, as previously described [23, 241.
tat cotransfection
In separate experiments, HMC were cotransfected with
HIV-1 LTR plasmid and another plasmid, pSVtat, containing
the HIV- 1 regulatory gene, tat. This plasmid was constructed
by cloning the Tat encoding gene downstream of SV4O pro-
moter sequences. Due to the strong transcriptional activity of
SV4O promoter sequences, transfection with this plasmid re-
sults in very high expression of Tat in transfected cells [25]. Tat
protein binds to its target sequence, TAR RNA, and trans-
activates the HIV- 1 LTR to significantly increase the produc-
tion of full length transcripts of HIV-l [19]. In cotransfection
experiments with the HIV-l tat gene, I g of DNA of the tat
gene containing the pSVtat plasmid was added to the calcium
phosphate incubations.
Treatment of HMC with growth factors
Two hours before harvesting the cells, culture media were
removed from the plates and replaced with unsupplemented
medium containing varying amounts of growth factors. The
growth factors tested were platelet derived growth factor
(PDGF), tumor necrosis factor alpha (TNF-a), transforming
growth factor alpha (TGF-a), and transforming growth factor /3
(TGF-/3), in concentrations of 10 ng/ml. For the TGF-/3 dose
dependent response study, cells were treated with 2.5, 25 and
250 pg/ml and 2.5 and 10 ng/ml concentrations of TGF-f3 (Sigma
Chemical Co.).
Assessment of candidate TGF-/3 responsive transcription
factors in HMC
TGF-/3 alters the expression of the Type 1 plasminogen
activator inhibitor gene through a 67 bp region containing
binding sites for two different transcription factors, CTF/NF-1,
and USF [26]. NF-KB, another transcription factor, plays a key
role in the activation of latent HIV virus by mitogens [19, 20,
27]. Since HIV-1 LTR contains the binding sites for USF,
NF-1, and NF-KB transcription factors, to determine whether
TGF-/3 mediates its effects through these transcription factors
in HMC, binding of NF-1, USF, and NF-KB to their respective
binding sites was studied in gel shift assays [19, 20, 26—28]. The
binding of SP- 1, a constitutively expressed general transcription
factor, to its binding site [29], was used as a control for the
specific TGF-/3 responsive transcription factors, NF-1, USF,
and NF-KB. Oligonucleotides containing the consensus se-
quences for the binding of NF-1, USF, NF-KB and SP-l were
designed and synthesized as previously described [26-29].
Nuclear extract was prepared from control HMC and HMC
treated with 10 ng/ml TGF-/3 for two hours by the method
of Dignam, Lebovitz and Roeder [30]. Double stranded oligo-
nucleotides were prepared by heat annealing the sense and
antisense oligonucleotides at their respective melting temp-
eratures, and were end-labeled in a kinase reaction by polynu-
cleotide kinase using high specific activity P32 ATP. Unincor-
porated nucleotide was removed by passing the labeled
oligonucleotides through a spin column of Sephadex G-25.
Nuclear extracts containing equal amounts of protein from
control and TGF-/3 treated HMC were incubated with labeled
oligonucleotides at room temperature in the presence of poly
dI.dC and binding buffer for twenty minutes. At the end of the
incubation period, a stop dye containing 50% glycerol and 0.5%
bromophenol blue and xylene cyanol was added to the reac-
tants. The nucleic acid-protein complexes were resolved on a
4% native polyacrylamide gel. HeLa cell nuclear extract (pre-
pared in a similar manner) was incubated with the probes in
identical reactions and complexes were resolved simulta-
neously.
Controls
For every set of experiments, HMC transfected with carrier
DNA, but treated with growth factors were included as con-
trols. For CAT assays, CAT enzyme activity was normalized
for the amount of protein in each sample and each set of
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Fig. 1. Transfection of human mesangial cells (HMC) with HIV-1 LTR
CAT plasmid. HMC were maintained and transfected with 6 zg of
plasmid DNA. Cytoplasmic lysate was prepared and the activity of
CAT enzyme was assayed. Lane I, untransfected cells; Lane 2, cells
transfected with HIV-l LTR CAT. A represents unacetylated chloram-
phenicol while B and C represent acetylated chloramphenicol.
experiments. Results are expressed as percent acetylation of
chloramphenicol at basal and experimental conditions. Each
experiment was performed at least three times. All the experi-
ments employed the same number of cells and except for dose
response studies, used the same amount of transfected DNA.
Differences between CAT activity responses of HMC exposed
to different doses of DNA or growth factors, or between HMC
treated with different growth factors were assessed by analysis
of variance, using Fisher's least square differences test to
examine pairwise differences between individual mean values.
Comparisons between HMC and HeLa cells treated under the
same conditions were assessed by paired t-test. Results were
considered significant if P < 0.05, and are expressed as mean
standard error.
Results
Transfection of human mesangial cells with HIV-i LTR gene
HMC in culture can be transfected successfully with HIV-l
5'-LTR (Fig. 1). In this experiment, HMC were transfected with
6 g of HIV-l LTR (pBenCAT) plasniid DNA. To determine
whether the level of HIV-l gene expression depended upon the
amount of transfected DNA, HMC were transfected with
varying amounts of plasmid DNA. As a control for the trans-
fection conditions, we transfected pBen CAT into HeLa cells,
an established transformed mammalian cell line. In such exper-
iments, both HMC and HeLa cells were transfected with 1 to 6
g pBen CAT plasmid DNA. The CAT activity in HMC was
comparable to that observed in HeLa cells at control condi-
tions, and at low doses of transfected DNA. There was a dose
dependent increase in CAT activity in response to increasing
the amount of transfected plasmid DNA in both HMC and
HeLa cells. CAT activity was significantly higher in HMC
transfected with 3 g HIV- 1 LTR DNA compared with control
conditions (without HIV-l LTR DNA), and in HMC transfected
with 4.5 pg DNA compared with HMC transfected with 1.5 g
HIV-l LTR DNA. In contrast, HeLa cells transfected with 4.5
j.g HIV LTR DNA exhibited greater CAT activity compared
with control conditions (without HIV-l LTR DNA), or with
HeLa cells transfected with 3 j.g HIV-l LTR DNA. There was
a marked and variable increase in CAT activity in HeLa cells
transfected with 6 g HIV- 1 LTR DNA compared to HeLa cells
transfected with lower doses of DNA or HMC transfected with
6 g HIV-1 LTR DNA. There was no statistically significant
difference, however, in CAT activity of HMC transfected with
3 and 6 j.g HIV-1 LTR DNA.
Response of HI V-i LTR gene transfected HMC to the HIV-i
regulatory protein TAT
To assess the function of the transfected HIV-l gene, the
effect of the HIV-l regulatory gene product, Tat, on the
transcriptional activity of HIV-l LTR was studied. Both HMC
and HeLa cells were cotransfected with 5 g of CAT plasmid
DNA and 1 g of the Tat encoding plasmid, pSVtat. Because of
the greatly increased tat mediated transactivation in HeLa cells
compared with HMC, the reactants were incubated 15 minutes
in HeLa cells and five hours in HMC. Baseline CAT activity
was 1.2 0.4% in HMC and 2.7 0.2 % in HeLa cells (P <
0.002). Upon cotransfection with pSVtat, CAT activity in-
creased to 24.6 8.4% in HMC (P <0.03). In contrast, upon
cotransfection with PSVtat, CAT activity increased more than
35-fold to 98.9 0.2% in HeLa cells (P < 0.0001).
The Tat mediated trans-activation in mesangial cells, as
assessed by CAT activity, was lower than that in HeLa cells. In
different sets of experiments, tat cotransfection resulted in
variable three- to 25-fold induction of CAT activity in HMC.
This may be attributed to the slower growth rate of mesangial
cells, which are a primary cell culture, compared to HeLa cells,
a stable transformed cell line. These results demonstrate that
HMC can be successfully transfected with HIV-1 genes, and
that the transfected gene is responsive to other HIV-1 regula-
tory gene products such as Tat.
HIV-i gene expression in transfected HMC exposed to
peptide growth factors
Mesangial cells transfected with the HIV-1 LTR CAT plas-
mid were treated with TGF-J3 and other growth factors, includ-
ing PDGF, TNF, and TGF-a, at a concentration of 10 ng/ml two
hours before harvesting the cells. We used this concentration of
growth factors since the growth of HMC in culture, as mea-
sured by thymidine incorporation, is induced in a linear fashion
by several growth factors up to the range of 10 ng/ml. At this
level the effect of such peptides on the growth of mesangial cells
is maximal [21]. Only TGF-/3, as compared to the other growth
factors, and their untreated control counterparts, caused a
several fold, significant increase in the CAT activity, compared
.
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Fig. 2. Effect of growth factors on HIV-1 LTR CAT expression in
human mesangial cells. Cells were transfected with 6 g plasmid DNA
as described earlier. In the case of cotransfection with tat, the pSV tat
plasmid was used. CAT activity was determined as described earlier.
After TLC and autoradiography, radioactive spots were counted in a
scintillation counter. The results are expressed as percent chloram-
phenicol acetylation. Growth factors were used at a concentration of 10
ng/ml. < 0.05 compared to control, ANOVA.
to control levels when assessed by analysis of variance (Fir,. 2).
The effect of treatment with 10 ng/ml TGF-f3 on CAT activity in
HMC was comparable to that of cotransfection with tat (5.8
1.4 vs. 5.4 0.5% acetylation, respectively). The magnitude of
the effect of tat cotransfection on HIV-1 LTR expression was
numerically similar to the response to TGF-13 treatment, al-
though both resulted in significantly increased CAT activity
compared to control HMC (transfected with carrier DNA). The
other growth factors either did not affect the CAT activity or
decreased it slightly. There was no difference between the CAT
activity assessed in transfected HMC exposed to PDGF,
TGF-a, TNF-a and that of untransfected cells.
In growth factor treatment experiments, Tat mediated induc-
tion of CAT activity was used as an index of HMC growth and
the efficiency of transfection. The experiments which resulted
in efficient Tat mediated trans-activation also showed induction
of CAT activity as a result of TGF-3 treatment. Growing the
HMC in serum free medium for 17 hours prior to TGF-13
treatment did not alter the degree of induction of CAT activity
(Fig. 3). Other investigators have used serum starved quiescent
cells when studying the effects of growth factors and cytokines
[21]. We incubated the cells in serum free medium for one hour
before adding the growth factors. As seen in Figure 3, no
significant effect of overnight serum starvation was observed in
our experiments, compared to studies done with one hours'
serum starvation.
Transforming growth factor-a increases the expression of
HIV-1 gene in a dose dependent manner in human mesangial
cells
We studied the effect of treatment with varying amounts of
TGF-p on the expression of the HIV-1 gene in HMC. HMC in
culture, after transfection with the HIV-1 LTR CAT plasmid,
were treated with varying amounts of TGF-/3 two hours before
harvesting the cells. The results are shown in Figure 4. There
was a gradual increase in the expression of HIV-l LTR in HMC
Fig. 3. Effect of overnight serum starvation on TGF-f3-induced HIV-J
LTR CAT expression. On the second day after transfection, after
removing the DNA precipitate, cells were supplemented with serum
containing medium for 5 hours. After 5 hours of incubation with serum,
cells were rinsed with unsupplemented medium and incubated with
serum deficient medium overnight. Twenty four hours later, the me-
dium was removed from the cells and replaced with fresh medium
devoid of serum, and cells were treated with TGF-/3 as described above.
The results are expressed as percent change compared to control (basal
level of activity).
treated with 2.5 to 25 pg/mI TGF-p, with a peak in CAT activity
at 25 pg/ml. The response at 2.5 pg/ml was significantly higher
than that of control HMC, untreated with TGF-13, and the
response at 2.5 and 10 ng/ml. There was no difference between
the HMC response when exposed to 25 pg/ml, compared with
2.5 and 250 pg/mI TGF-f3; however, the CAT activity in cells
exposed to 2.5 pg/ml was significantly increased compared to
the response of cells exposed to higher TGF-/3 concentrations
of 2.5 and 10 nglml. There was no difference between the
response of HMC to TGF-f3 in concentrations of 250 pg/mi
compared to 2.5 and 10 ng/ml, suggesting a peak response of
HIV-l gene expression occurs in the range of 2.5 to 25 pg/mI
TGF-/3 (Fig. 4).
Assessment of candidate TGF-/3 responsive transcription
factors in HMC
Because of the results of our experiments suggesting TGF-13
increased HIV- 1 LTR gene expression in HMC, we wished to
determine whether this effect was mediated through transcrip-
tion factors known to be affected by the growth factor. SP-l, a
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Fig. 4. Dose dependent effect of TGF-/3 on the expression of H!V-J
LTR CAT in human mesangial cells. HMC in culture were transfected
with the plasmid pBen CAT as described earlier. Transfected HMC
were treated with 2.5 pg/mI to 10 ng/ml TGF-p for two hours before
harvesting the cells. CAT enzyme in the cytoplasmic fraction was
assayed as described above. Results are expressed as percent chloram-
phenicol acetylation. *p < 0.05 compared to control, 2500, and 10,000
pg/mi TGF-/3, ANOVA. **p < 0.05 compared to 2500, 10,000 pg/ml
TGF-13, ANOVA.
general transcription factor [29], was used as a control for the
specific TGF-/3 responsive transcription factors, NF-1, USF,
and NF-KB. Cell nuclear extracts were incubated with oligonu-
cleotide probes for the above-mentioned transcription factors.
HeLa nuclear extracts showed characteristic binding to all the
transcription factors studied. HMC extracts showed lower
nuclear factor binding and formed faster migrating DNA-pro-
tein complexes for all the specific transcription factors studied,
compared to HeLa cells, perhaps reflecting the different nature
of the two cell types (Fig. 5). NF-1 and NF-KB responsive
element containing oligonucleotides showed greater binding
compared to USF and SP-1 oligonucleotides in the control
HMC nuclear extracts. HMC nuclear extracts formed a faster
migrating complex with the USF oligonucleotide compared to
the response in HeLa cells, We did not observe SP-1 oligonu-
cleotide binding in HMC nuclear extracts, although DNA-
protein complexes were present in HeLa cell nuclear extracts
after incubation with the appropriate oligonucleotide probe.
These findings may reflect a differential presence of specific
transcription factors in HMC compared to HeLa cells. No
effect of TGF-/3 treatment was observed on the binding of NF-1
or NF-KB transcription factors to their respective binding sites.
These results suggest another set of responsive elements or
another transcription factor may mediate the TGF-/3 effect
increasing HIV-1 LTR expression in HMC.
Discussion
The common renal syndromes encountered in HIV-infected
patients include renal insufficiency and nephrotic range protein-
uria associated with FGS, and various proliferative glomerulo-
nephritides [1, 3,4,6, 31]. FGS is characterized by expansion of
the glomerular mesangium (which decreases the glomerular
filtration surface) and increased production of mesangial matrix
components, mainly laminin, collagen, fibronectin, and proteo-
glycans [321. Renal function in patients with HIVAN may
progress from relatively normal to complete end-stage renal
disease, necessitating dialysis, over a period of several days to
weeks [1, 31, 33]. This rapid progression of disease is not
characteristic of other renal diseases in which glomerulosclero-
sis is seen, such as diabetic nephropathy or heroin associated
nephropathy.
It is not known whether productive infection of kidney cells
with HIV-1 results in renal disease. We and others have
observed that renal biopsy tissue of HIV- 1 infected patients
contains HIV-l genes [5, 6]. Cohen et al demonstrated the
presence of HIV genomic material by in situ hybridization
techniques in glomerular and tubular epithelial cells in renal
biopsy tissue from HIV-infected patients with FGS, and im-
mune complex nephropathy [6]. They also identified hybridiza-
tion product in one of the five renal biopsy specimens studied
from patients without clinical or pathological evidence of renal
disease [6]. Results from our laboratory also indicate that the
presence of HIV- 1 genome can be demonstrated by the poly-
merase chain reaction in the overwhelming majority of renal
tissue studied from HIV infected patients, both with and
without clinical or pathologic evidence of renal disease [5].
Such data suggest that the presence of HIV genomic material in
renal tissue is not sufficient to result in disease. Presumably,
some inherent predisposition and/or triggering factor must be
present to initiate pathologic processes.
Green, Resnick and Bourgoignie demonstrated that HMC in
cell culture can be infected with HIV-l virus [7]. Preliminary
evidence from another laboratory corroborates their findings
[8]. Growth factors and cytokines indirectly affect the transcrip-
tional efficiency of promoters by increasing the binding of
transcription factors to promoters. In order to investigate the
effect of such peptides on HIV-infected renal tissue, we trans-
fected an HIV-1 LTR gene segment of HIV-l, the equivalent of
a promoter element, into HMC. Viral LTR contains the neces-
sary sequence elements required for the binding and interaction
of cellular transcription factors [19]. Our results demonstrate
that HMC can be transfected with an HIV-1 gene. To determine
whether the transfected gene was functional and responsive to
other HIV-1 gene products, HMC were cotransfected with an
HIV-1 LTR containing plasmid and a plasmid containing the
gene for the HIV-1 regulatory protein Tat. Tat binds to the
trans-activation responsive region (TAR) in the viral RNA and
increases the production of full length viral mRNA transcripts
[19]. We and others have shown the requirement of host specific
factors for Tat mediated TAR trans-activation [19, 34, 35].
Cotransfection of HMC with tat resulted in a several fold
increase in CAT activity, demonstrating that the transfected
HIV-1 gene was functional.
Several cytokines and growth factors can modulate the
growth of HMC in cell culture. Important among these are
platelet-derived growth factor (PDGF), epidermal growth factor
(EGF), interleukin-l (IL-l], tumor necrosis factor (TNF), and
transforming growth factors a and /3 [9, 12, 13, 36—38]. These
agents, which significantly modulate the growth and prolifera-
tion of mesangial cells, may be produced by circulating white
blood cells or may be secreted by mesangial cells [9, 13—14]. A
number of these substances can increase the expression of HIV
genes [19]. A role for cytokines and growth factors in the
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Fig. 5. Response of transcription factors to
TGF-13 treatment in human mesangial cells.
Nuclear extract from HeLa cells, control and
TGF-/3 treated HMC were prepared according
to the method of Dignam et al.
Oligonucleotide probes end labeled with P32
were incubated with equal amounts of nuclear
extract protein and poly dI.dC as described.
Nucleic acid-protein complexes were resolved
on a 4% native polyacrylamide gel. The DNA-
protein complexes are indicated by arrows.
Lanes 1,4,7, and 10: Binding of HeLa nuclear
proteins to oligonucleotides containing
consensus binding sites for SP-1, NF-l, NF-
KB, and USF, respectively. Lanes 2, 5, 8, and
11: Binding of control HMC nuclear proteins
to oligonucleotides containing consensus
binding sites for SP-l, NF-1, NF-KB, and
USF, respectively. Lanes 3, 6, 9, and 12:
Binding of TGF-f3 treated HMC nuclear
proteins to oligonucleotides containing
consensus binding sites for SP-l, NF-l, NF-
KB, and USF, respectively. HMC show lower
binding of nuclear proteins to all transcription
factors studied.
activation of latent HIV- 1 virus has also been suggested [19—
20]. Cytokines and growth factors, due to their mitogenic
effects, cause the activation of transcription factors whose
increased binding to LTR may result in increased transcription
of the HIV genome [19]. The presence of HIV-l genes in the
renal tissue of HIV- 1 infected patients, with or without renal
disease, suggests that local factors in the kidney may alter the
expression of HIV-l genes, which may ultimately lead to renal
dysfunction. This notion is consistent with our finding of
abnormal tubular and glomerular protein excretion in HIV-
infected patients without clinical evidence of renal disease [39].
TGF-/3 has been implicated in the development of glomeru-
losclerosis in experimental animal models [10—12, 38], and has
been shown to alter HIV replication in a cell type specific
manner [15, 18]. Elevated plasma and tissue levels of TGF-j3 in
HIV-1 infected patients have been reported [15—17, 40]. To test
whether TGF-/3 affects HIV gene expression in renal cells, we
treated HMC in cell culture with TGF-J3 and other growth
factors. Of the various growth factors tested, only treatment
with TGF-/3 caused a significant increase in the transcriptional
activity of HIV-l LTR. TGF-f3 treatment of HMC with various
doses resulted in a dose-dependent increase in LTR expression.
The effect was maximal and unchanged between 2.5 and 250
pg/mI. This result is consistent with the reported biphasic effect
of TGF-13 treatment on the growth of mesangial cells [10, 21, 36,
41]. In human mesangial cells, lower concentrations stimulate
HMC growth, but TGF-13 inhibits cellular proliferation at higher
concentrations [21]. Jaffer et a! [21] reported a dose-dependent
inhibitory effect of TFG-p on the growth of HMC induced by
PDGF up to a concentration of 1 nglml, but a reversal of this
inhibitory effect was observed at higher concentrations of up to
10 ng/ml TGF-/3. The inducing effect of TGF-f3 on HIV-1 LTR
activity could be specific to HMC due to its effect on specific
transcription factors. Alternatively, its effect in vivo might be
critically modulated by the presence of local cytokines and
growth factors.
Our gel shift studies suggest that TGF-/3 does not mediate its
effect through NF-1 and NF-KB, transcription factors with
binding sites present in HIV-l LTR [19]. These results may be
related to the specific types and levels of transcription factors
and oligonucleotides employed in the present studies. Alterna-
tively, the transcription factors may require additional activa-
tion in HMC. Finally, inactivated forms of the transcription
factors may be present to a greater extent in slow growing,
non-transformed cells such as HMC, compared to HeLa cells,
a transformed cell line. Cell-specific transcriptional regulatory
factors or other transcription factors may mediate these phe-
nomena. Further studies will be necessary to elucidate the roles
of each of these mechanisms in HMC.
Our preliminary data provide a potential explanation for the
rapidly progressive acute renal failure, characterized patholog-
ically by FGS, seen in patients with HIV infection. These
results are clinically relevant since elevated TGF-/3 levels have
been reported in patients with AIDS and in cells infected with
HIV-l in vitro [15, 16].
Theoretically, high circulating TGF-f3 levels, such as are
found in patients with HIV infection or AIDS, or local renal
TGF-13 production, might induce increased matrix production in
HMC or other renal cells, infected or uninfected with HIV.
Such increase in matrix has been demonstrated to be associated
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with decreased renal function in patients with diabetic nephrop-
athy [42] and FGS [32]. Recently, increased circulating TGF-/3
levels have been demonstrated in patients with renal insuffi-
ciency [43]. Such increased cytokine levels might induce an
increase in the growth and matrix production of HMC and other
renal cells through autocrine or paracrine pathways, and/or
increased expression of HIV-l genes in infected renal cells.
HIV gene expression, might, in turn, result in increased TGF-/3
synthesis in renal tissue. We have recently assessed tissue
levels of TGF-f3 in renal biopsies from patients with HIVAN,
which were in the range of the peak response of HIV-l LTR
expression demonstrated in our TGF-/3 dose-response experi-
ments (Phillips TM, Kimmel PL, unpublished data). These
results are consistent with an autocrine or paracrine mechanism
of TGF-/3 effecting net renal matrix synthesis. In addition to
increasing its own cellular production, TGF-/3 may interfere
with matrix degradation by decreasing the synthesis of pro-
teases and increasing levels of protease inhibitors [381. Such
cellular events might lead to a vicious cycle of cytokine-induced
cellular hypertrophy and matrix production, renal fibrogenesis
and renal insufficiency, and, as a consequence, further cyto-
kine-induced HMC dysfunction. Such a developing cycle is
consistent with the rapid progression to global sclerosis and end
stage renal disease seen in patients with HIV infection and
nephropathy. The effect of TGF-f3 to cause growth without
proliferation, in susceptible kidney tissue, might result in the
development of increased extracellular matrix, without glomer-
ular inflammation, characteristic of HIV-associated FGS. Fur-
ther investigation in in vitro systems and in renal tissue from
HIV infected patients with and without renal disease is neces-
sary to elucidate more completely the role of TGF-j3 in the
pathogenesis of the renal diseases associated with HIV infec-
tion.
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